靶向雙腫瘤相關抗原（tumor-associated antigen，TAA）的雙抗ADC（bispecific ADC）具有多種潛在抗腫瘤優勢：

1. 同時靶向雙腫瘤驅動分子，克服耐藥性；

2. 識別雙TAA共表達的腫瘤細胞，增加靶向腫瘤特異性，降低脫靶毒性；

3. 雙靶點組合產生新的內吞動力學機製，更高效的殺傷腫瘤；

4. 提高腫瘤的ADC富集和暴露，有助於更強和更長久的殺傷異質性腫瘤。

尊龙凯时人生就是搏官网新型雙抗ADC平台優勢

1. RenLite來源的共同輕鏈抗體易於構建雙抗分子，且性質穩定易於後期開發，顯著降低了CMC工藝開發難度
2. 靶點敲除（KO）小鼠免疫獲得的抗體表位豐富，多物種交叉且物種間親和力接近
3. 具有自主知識產權的Linker&Payload平台BLD1102
   
4. 候選靶點多，多物種檢測藥效和毒性，開發周期短成功率高

新型Linker & Payload平台BLD1102

尊龙凯时人生就是搏官网已開發出具有自主知識產權的新型ADC平台BLD1102。

1）該平台使用的payload是新型拓撲異構酶1抑製劑BCPT02，具有廣譜、強效的腫瘤殺傷能力

2）獨特設計的可裂解linker具有優異親水特性，賦予ADC如單抗般的親水性質，極大改善了ADC的理化性質

3）BLD1102具有高度的血漿穩定性及更強效的腫瘤殺傷，

4）在臨床前非人靈長類動物安全性評價中展示出良好的耐受性，是優異的新一代ADC技術平台。

基於RenLite平台的雙抗ADC構建

基於RenLite的尊龙凯时人生就是搏官网雙抗ADC平台小視頻

貨架型TAA抗體骨架序列

20+在研雙抗ADC，開放合作

海報下載

Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)

AACR 2024: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

AACR 2024: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

AACR 2024: A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

AACR 2024: BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

AACR 2024: A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

SITC 2023: *DM001, a novel TROP2xEGFR bsADC, demonstrates potent tumor growth inhibition in preclinical models and favorable safety profile in monkey

SITC 2023:Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1

SITC 2023: *DM005, an EGFR х MET bsADC with a novel DNA topoisomerase I inhibitor payload, showed robust anti-tumor activity in preclinical models

SITC 2023: BSA01, a bsADC targeting EGFR and membrane-bound MUC1-C, exhibits anti-tumor efficacy in vivo

SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types

SITC 2023: A novel bsADC targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy 

AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity 

AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET 

AACR2023：Discovery of BCG033, A Novel Anti-PTK7xTROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer 

AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy

AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1

AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate 

IO Summit EU 2023: YH013, a Common Light Chain Bispecific ADC Targeting EGFR and MET, Improves Preclinical Efficacy Over Its Parental Single-Targeting ADCs 

AACR 2022：YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy  

World ADC San Diego2022：YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 

PEGS EUROPE 2022：YH013, a fully-human EGFR x c-MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy 

相關新聞

尊龙凯时人生就是搏官网與ABL Bio達成合作，共同開發新型雙抗ADC藥物

尊龙凯时人生就是搏官网與Radiance Biopharma達成雙抗ADC協議

網絡研討會

April 24, 2024 | Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload

July 19, 2023 | Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety